Moloney Securities Asset Management, LLC Allogene Therapeutics, Inc. Transaction History
Moloney Securities Asset Management, LLC
- $787 Million
- Q3 2025
A detailed history of Moloney Securities Asset Management, LLC transactions in Allogene Therapeutics, Inc. stock. As of the latest transaction made, Moloney Securities Asset Management, LLC holds 514,000 shares of ALLO stock, worth $632,220. This represents 0.08% of its overall portfolio holdings.
Number of Shares
514,000
Previous 267,500
92.15%
Holding current value
$632,220
Previous $302,000
110.93%
% of portfolio
0.08%
Previous 0.04%
Shares
3 transactions
Others Institutions Holding ALLO
# of Institutions
182Shares Held
138MCall Options Held
76.6KPut Options Held
36.2K-
Tpg Gp A, LLC Fort Worth, TX18.7MShares$23 Million1.5% of portfolio
-
Black Rock Inc. New York, NY16.4MShares$20.2 Million0.0% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il14MShares$17.2 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA9.02MShares$11.1 Million0.0% of portfolio
-
Primecap Management CO Pasadena, CA7.08MShares$8.71 Million0.01% of portfolio
About Allogene Therapeutics, Inc.
- Ticker ALLO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 143,807,008
- Market Cap $177M
- Description
- Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult p...